IP Library › Granted Patent US 11,198,729
Granted Patent B2
US 11,198,729 · App. 16/448,053 · Granted Dec 14, 2021

Immunologic effector cell of targeted CLD18A2, and preparation method and use thereof

Inventors: Huamao Wang (Shanghai, CN); Bo Song (Shanghai, CN); Xiumei Cai (Shanghai, CN)
Assignee: Cafa Therapeutics Limited
C07K16/28A61K35/17A61K48/00C07K14/7051C07K14/70517C07K14/70521C07K14/70578C07K19/00C12N5/10C12N15/62C12N15/867A61K2035/124C07K2317/53C07K2317/622C07K2319/02C07K2319/03C07K2319/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,198,729
App. No.
16/448,053
Granted
Dec 14, 2021
Kind
B2
Abstract

Disclosed are a chimeric antigen receptor (CAR) targeting CLD18A2, and preparation method and use thereof. The extracellular binding region of the CAR comprises a protein specifically recognizing CLD18A2. The immune effector cell modified by the CAR can be used to treat tumors such as pancreatic cancer and stomach cancer.

Claims (11)

1. A method for inducing cytotoxic effect against CLD18A2 positive cells, comprising contacting said CLD18A2 positive cells with immune effector cells having a chimeric antigen receptor (CAR) expressed, said CAR comprising an extracellular binding region, a transmembrane region and an intracellular signal region, wherein said extracellular binding region specifically recognizes CLD18A2.

2. The method of claim 1 , wherein said extracellular binding region comprises an antibody which specifically recognizes CLD18A2.

3. The method of claim 2 , wherein said antibody is a single-chain antibody or a single-domain antibody.

4. The method of claim 1 , wherein said extracellular binding region comprises an amino acid sequence having SEQ ID NO: 4 or SEQ ID NO: 6.

5. The method of claim 1 , wherein said transmembrane region has a sequence comprising the sequence of transmembrane region and hinge region of CD8 or CD28.

6. The method of claim 1 , wherein said intracellular signal region sequence is selected from the following: the intracellular signal region sequence of CD3ζ, FcεRIγ, CD27, CD28, CD137, CD134, or a combination thereof.

7. The method of claim 1 , wherein said immune effector cells comprise T lymphocytes, NK cells or NKT cells.

8. The method of claim 1 , wherein said CLD18A2 positive cells are tumor cells.

9. The method of claim 1 , wherein said immune effector cells are transduced by a nucleic acid having a sequence of SEQ ID NO: 3 or SEQ ID NO: 5.

10. The method of claim 9 , wherein said immune effector cells are transduced by an expression vector comprising said nucleic acid.

11. The method of claim 10 , wherein said expression vector is derived from lentivirus plasmid.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2022
From: CAFA THERAPEUTICS LIMITED
To: CRAGE MEDICAL CO., LIMITED
Reel/Frame 061439/0180 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2021
From: CARSGEN THERAPEUTICS LIMITED
To: CAFA THERAPEUTICS LIMITED
Reel/Frame 055762/0709 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2019
From: WANG, HUAMAO; SONG, BO; CAI, XIUMEI
To: CARSGEN THERAPEUTICS LTD.
Reel/Frame 050440/0942 →
Priority Claims (1)
CN 201410341504.X · Jul 17, 2014 · national
Continuity (2)
Continuation 15326974
Related Publication 20200172613A1 · Jun 4, 2020
Cited By (1)
US 12,186,343